CREEK & RIVER (4763) Q1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2024 earnings summary
20 Jul, 2026Executive summary
Q1 FY25 sales rose 1% year-over-year to ¥12,854 million, while operating profit fell 20.2% to ¥1,261 million, reflecting upfront investments and a record number of new graduate hires.
Profit attributable to owners of parent decreased 17.7% year-over-year to ¥860 million.
Creative (Japan) and Medical segments saw sales and profits slightly below plan, but project acquisition is increasing for the second half.
Earnings per share for the quarter were ¥39.67, down from ¥47.42 in the prior year.
Financial highlights
Gross profit margin declined to 39.3% from 40.6% year-over-year, with gross profit at ¥5,056 million, slightly down from ¥5,177 million.
SG&A expenses increased 5% year-over-year to ¥3,794 million, raising the SG&A rate to 29.5%.
Ordinary profit fell to ¥1,277 million, a 19.9% decrease year-over-year.
Comprehensive income for the quarter was ¥885 million, down from ¥1,033 million year-over-year.
Cash and deposits increased by ¥247 million to ¥11,716 million.
Outlook and guidance
Full-year sales guidance is ¥55 billion (+10.4% YoY), with operating profit targeted at ¥4.8 billion (+17% YoY).
Profit attributable to owners of parent for the full year is forecast at ¥3,100 million, up 16.6% year-over-year.
Full-year earnings per share forecast is ¥140.93.
Creative (Japan) and Medical segments expected to recover in the second half as project acquisition rises.
Dividend forecast raised to ¥43 per share.
Latest events from CREEK & RIVER
- Sales up 2.3% but operating profit down 15.6%; AI/DX and overseas growth prioritized.4763
Q2 202420 Jul 2026 - Sales up 1% YoY, profits down double digits, dividend cut, treasury buyback and new initiatives.4763
Q3 202520 Jul 2026 - Record sales and lower profits in FY2025; strong growth and higher dividends forecast for FY2026.4763
Q4 202520 Jul 2026 - Record sales and profit growth, with acquisitions fueling further expansion.4763
Q1 202620 Jul 2026 - Net sales rose 8.7% and profit attributable to owners of parent surged 50.7%.4763
Q2 202620 Jul 2026 - Record sales and profit growth fueled by new segments, M&A, and strong business performance.4763
Q3 202620 Jul 2026 - Record sales and double-digit profit growth, with sales growth forecast to continue.4763
Q4 202620 Jul 2026 - Record Q1 sales and profits, driven by creative, medical, and incubation growth.4763
Q1 202720 Jul 2026